HRSA has ordered Akorn Inc. and BioComp Pharma to repay 340B covered entities for overcharges following audits.

HRSA Orders Two Drug Makers to Repay 340B Entities After Audits Show Overcharges

In Federal, Pharma Industry, RegulatoryOctober 26, 2021524 Views

The U.S. Health Resources Services Administration (HRSA) has ordered two drug manufacturers that it audited—Akorn Inc. and BioComp Pharma—to repay 340B covered entities for overcharges.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Tom Mirga

Exact matches only

Search in title

Search in content

Search in excerpt

Hidden